Medication Combo Improved Weight Loss When Added to Lifestyle Modifications
Controlled-release phentermine/topiramate combined with lifestyle modifications appears to be an effective option for sustained treatment of obesity complicated by cardiometabolic disease....
Advertisement
"Controlled-release phentermine/topiramate was also associated with sustained improvements in the clinical manifestations of weight-related cardiometabolic disease, including hyperglycemia, dyslipidemia and elevated blood pressure, despite reduced use of concomitant medications," the researchers wrote.
The researchers conducted a placebo-controlled, double blind, 52-week extension study in which volunteers continued with the original randomly assigned treatment to complete a total of 108 weeks. The groups received placebo, 7.5 mg phentermine/46 mg controlled-release topiramate or 15 mg phentermine/92 mg controlled-release topiramate. All of the volunteers participated in a lifestyle modification program.
The extension study included 676 participants, and 84% of them completed the study. At week 108, controlled-release phentermine/topiramate was associated with a significant sustained weight loss compared with placebo (P<.0001). For placebo, the mean percentage of body weight change from baseline was –1.8%, vs. –9.3% for the 7.5-mg/phentermine/46-mg topiramate group and –10.5% in the 15-mg phentermine/92-mg topiramate group.
Significantly more participants treated with controlled-release phentermine/topiramate achieved weight loss of at least 5%, 10%, 15% and 20% vs. placebo. Controlled-release phentermine/topiramate also improved cardiovascular and metabolic variables, and decreased rates of diabetes compared with placebo. Controlled-release phentermine/topiramate was well tolerated and associated with reduced adverse event rates between weeks 56 and 108 compared with weeks 0 to 56.
"The unmet clinical need for effective weight-loss medications, together with the favorable risk–benefit profile in the current study, suggests that controlled-release phentermine/topiramate in conjunction with a lifestyle-intervention program could be a valuable therapeutic approach to counteract increasing rates of obesity and its related complications," the researchers wrote.
Garvey WT. Am J Clin Nutr. 2011;doi:10.3945/ajcn.111.024927.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2012 Diabetes In Control, Inc.. All rights reserved.